Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer

Future Oncology
S S Dawood, Bhawna Sirohi

Abstract

Pertuzumab is a humanized monoclonal antibody targeting HER2 that is different from trastuzumab in that it binds to a different domain of HER2; hence, combining the two drugs leads to a more comprehensive blockade of the receptor. This is the first drug to receive fast-track approval from US FDA based on the pathologic complete response (as the primary end point) attained in patients treated with neoadjuvant chemotherapy for breast cancer. Pertuzumab is approved in first-line treatment in metastatic setting both by FDA and EMA in combination with trastuzumab and docetaxel. Combining two targeted therapies ('dual blockade') will certainly escalate treatment costs and it remains to be seen if this strategy will find its way in to the clinic for all patients.

References

Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Oct 7, 2003·Molecular Cell·Antony W BurgessShigeyuki Yokoyama
Feb 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David B AgusGwen Fyfe
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chia C PorteraSandra M Swain
Jul 18, 2008·Cancer Research·Si Tuen Lee-HoeflichHoward M Stern
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaLuca Gianni
Jun 15, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LenihanJ Baselga
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Feb 3, 2012·Cancer Research·Yunqing Li, John Laterra
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Aug 15, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Otto Metzger-FilhoIan Krop
Mar 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LenihanJ Baselga

❮ Previous
Next ❯

Citations

Apr 29, 2015·Molecular Immunology·J M RedmanL M Weiner
Jan 1, 2017·JCO Precision Oncology·Amber JohnsonFunda Meric-Bernstam
Jan 7, 2021·Heart Failure Reviews·Diana GonciarLucia Agoston-Coldea
Nov 16, 2016·ESMO Open·Noam F PondéEvandro de Azambuja

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Clinical Trials Mentioned

NCT01358877
NCT01996267
NCT01583426
NCT01796197
NCT01937117
NCT01120184
NCT01565083
NCT01572038
NCT01026142
NCT01777958

Software Mentioned

CLEOPATRA

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Journal of the National Comprehensive Cancer Network : JNCCN
Komal Jhaveri, F J Esteva
Pharmacogenomics and Personalized Medicine
Kerry ReynoldsDon S Dizon
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
S VrbicM Vrbic
Anticancer Research
Philippe BarthélémyJean-Emmanuel Kurtz
© 2021 Meta ULC. All rights reserved